Controversies in iron management Management of comorbidities in kidney disease in the 21st century: Anemia and bone disease by Nissenson, Allen R. & Charytan, Chaim
Kidney International, Vol. 64, Supplement 87 (2003), pp. S64–S71
Controversies in iron management
ALLEN R. NISSENSON and CHAIM CHARYTAN
Department of Medicine, Division of Nephrology, David Geffen School of Medicine, UCLA, Los Angeles, Calfornia; and
Department of Medicine, Division of Nephrology, New York Hospital Medical Center of Queens
Controversies in iron management.
Background. Iron therapy is required in hemodialysis pa-
tients receiving erythropoietic stimulators in order to achieve
the target hemoglobin in the most efficient way. While oral
iron has been disappointing in this regard, parenteral iron has
been widely used, despite a significant incidence of severe side
effects when iron dextran is used. The recent availability of a
more effective form of oral iron (heme-iron), and safer forms
of parenteral iron (iron sucrose and iron gluconate) has made
iron management in this population simpler. Many questions
remain, however, about the use, efficacy, and safety of these
compounds in hemodialysis patients.
Methods. Current literature was reviewed and combined
with the authors’ clinical experience to address a number of
current questions regarding the use of iron in hemodialysis
patients.
Results. Although oral non-heme iron is infrequently suffi-
cient to maintain iron stores in hemodialysis patients, recent
studies suggest that heme-iron may be more useful in this
regard. Heme-iron is absorbed to a greater extent than non-
heme iron, and is better tolerated. Small studies have shown
that when heme-iron is administered, less parenteral iron and
lower doses of erythropoietin (EPO) are needed to maintain
target hemoglobin. Current evidence suggests that both iron
sucrose and iron gluconate are safer than iron dextran, and
the latter should only be used in extraordinary circumstances.
While in vitro studies have demonstrated some differences in
the effects of iron sucrose and iron gluconate on cellular toxic-
ity, the clinical importance of these has not been determined.
Both compounds can be used safely for repletion and mainte-
nance therapy, and doses of up to 300 mg of either are generally
well tolerated when such higher doses are needed, as in perito-
neal dialysis (PD) patients or chronic kidney disease (CKD)
patients not on dialysis.
Conclusion. A number of questions remain regarding the
appropriate use, efficacy, and potential toxicity of iron therapy
in dialysis patients. Further prospective research should ad-
dress the myriad questions raised in this review.
When chronic hemodialysis was initially utilized, it
quickly became clear that anemia was a highly prevalent
accompaniment to end-stage renal disease (ESRD). Be-
cause of the severity and clinical symptoms associated
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with anemia, patients frequently received blood transfu-
sions. One of the consequences of multiple blood trans-
fusions, in the context of low endogenous erythropoi-
etin (EPO) levels, was progressive accumulation of iron
throughout the body. This was manifested by extremely
high serum ferritin levels, often 1500 to 5000 ng/mL;
however, specific organ dysfunction related to this excess
body iron was difficult to detect. When recombinant
EPO (rHuEPO) was approved in 1989 and erythropoie-
sis was stimulated, this accumulated iron was rapidly
mobilized and serum ferritin levels fell precipitously [1].
In the current era of rHuEPO-stimulated erythropoiesis,
sufficient iron is needed to optimize the hemoglobin re-
sponse, illustrating that an appropriate balance between
erythropoietic stimulation, and provision of the key sub-
strate for hemoglobin production, iron, is essential [2].
The need for ongoing iron replacement stimulated re-
search into the value of oral iron in meeting this need,
as well as the use of a variety of parenteral irons, only
one of which, iron dextran, was available in the United
States and many other parts of the world through the
1980s. Most recently, carbohydrate forms of parenteral
iron have become widely available, purporting to be safer
and as efficacious as iron dextran [3, 4].
With the greatly increased use of parenteral iron in
ESRD patients, the safety and efficacy of available com-
pounds has come under increasing scrutiny, with many
unanswered questions remaining [5–7]. This paper will
address a number of these key questions, and the reader
is referred to recent reviews of the carbohydrate irons
for more detailed information of those compounds [3, 4].
Wherever possible, we have relied on the best available
medical evidence to provide the answers to the key ques-
tions. Where evidence is lacking we provide our best
recommendations based on our own knowledge and ex-
perience, and extensive discussions with clinicians and
researchers working in this area.
IS THERE ANY VALUE OF ORAL IRON
IN HEMODIALYSIS PATIENTS
RECEIVING rHuEPO?
Numerous studies have shown that the increased de-
mand for iron driven by stimulated erythropoiesis in
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ESRD patients receiving rHuEPO, coupled with ongo-
ing significant iron loss from a variety of sources in hemo-
dialysis patients, make it difficult for traditional forms
of oral iron to sufficiently meet the iron needs of this
patient population [8–11]. Compounding the problem is
the limited absorption of these forms of oral iron, and
the poor patient tolerance, the latter primarily related
to gastrointestinal side effects. Recent evidence suggests,
however, that heme-iron polypeptide (HIP), a new gen-
eration of oral iron product, may overcome these limita-
tions of traditional forms of oral iron and be effective
as a form of iron replacement in this patient population
[12, 13]. HIP uses the heme porphyrin ring to supply
iron to the key sites of intestinal absorption, which differ
from those for non-heme iron. HIP is produced by hydro-
lysis of bovine hemoglobin using a technique that leaves
peptides from the hemoglobin subunits covalently bound
to the heme ring, increasing solubility at low pH. In
normal volunteers, the bioavailability of HIP has been
found to be up to 10 times higher than non-heme iron
[14, 15]. In a pilot study in hemodialysis patients it was
reported that the use of HIP led to a significant decrease
in intravenous (IV) iron and rHuEPO use, while main-
taining a constant hemoglobin level [12]. A recent open-
label, multicenter study was performed in hemodialysis
patients previously on maintenance IV iron [13]. IV iron
was discontinued and replaced with HIP, and patients
were evaluated over a 6-month period. Patients receiving
HIP and no IV iron were able to maintain iron parame-
ters in the Kidney Disease Outcomes Quality Initiative
(KDOQI) recommended range, as well as stable hemo-
globin levels. Of note, three patients dropped out of the
study because of GI symptoms (bloating and flatulence).
It appears that HIP may offer an alternative approach
to iron management in hemodialysis patients, providing
sufficient iron to sustain rHuEPO-driven erythropoiesis,
with good patient tolerance. Practical considerations, in-
cluding the out-of-pocket costs to patients, and the incon-
venience of taking additional oral medications, may be
important determinants of the diffusion of HIP into clini-
cal practice.
SHOULD IRON DEXTRAN BE USED IN ESRD
PATIENTS WHEN IRON SUCROSE AND/OR
IRON GLUCONATE ARE AVAILABLE?
There are clear and convincing data to show that iron
dextran is associated with serious allergic side effects in
a small fraction of patients, and that on rare occasions
such allergic reactions are fatal [16–18]. It is also appar-
ent that there are no methods currently available to
predict which patients will have such allergic reactions,
since these may occur despite a “negative” test dose, and
after many unremarkable injections of the drug [11]. On
the other hand, iron sucrose and iron gluconate are not
associated with severe allergic reactions (and possibly
are not allergenic at all), and deaths associated with these
agents have not been reported [19, 20]. The routine use
of iron dextran, therefore, cannot be justified in ESRD
patients on hemodialysis. For chronic kidney disease
(CKD) or those ESRD patients who require parenteral
iron but are not on in-center hemodialysis, the best ap-
proach is less clearly defined. For such individuals, high-
dose (500 to 1000 mg) iron dextran therapy is often
prescribed and tolerated, but the frequency of significant
adverse events is not well described. Higher doses of
iron sucrose or iron gluconate, in these situations, appear
to be safer and better tolerated than iron dextran, but
this experience is preliminary and limited [21–23] (see
also references 56 and 57). The clinician must weigh the
inconvenience to the patient of multiple infusions of
these agents or their use by as yet to be established high-
dose regimens against the possibility of a severe reaction
to iron dextran.
DOES A PHYSICIAN NEED TO BE PRESENT
WHEN PARENTERAL IRON IS GIVEN?
When iron dextran is used, it is essential that a physi-
cian be present during the infusion because of the possi-
bility of a severe allergic reaction. Prompt treatment
of an anaphylactic reaction may be life saving in this
circumstance, and even though dialysis staff should be
trained in basic life support techniques, the presence and
leadership of the nephrologists in this regard is invalu-
able to ensuring a good clinical outcome. Although some
non-allergic reactions may occur when iron sucrose or
iron gluconate are infused, these are not life threatening
and can be easily managed by dialysis staff. The presence
of a physician during the administration of these two
compounds is not medically necessary.
IS IRON OVERSATURATION REAL, OR A
FINDING BASED ON FAULTY LABORATORY
METHODOLOGY?
There has been clear documentation of high serum
iron levels in children following iron poisoning, sufficient
enough to exceed the number of transferring binding
sites [24]. Concern that such oversaturation also occurs
following IV iron administration, particularly when the
carbohydrate irons are used in dialysis patients, was ini-
tially raised by Zanen et al [25] in a still quoted paper that
has been clearly shown to be methodologically flawed.
Seligman and Schleicher [26] showed convincingly that
methodologies to measure serum iron, in particular those
using an ascorbic acid/guanidine buffer method, cause
in vitro dissociation of iron bound to its carrier (i.e.,
gluconate or dextran), thus leading to a falsely elevated
transferrin saturation value. Subsequent studies of iron
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gluconate, where appropriate analytical techniques are
used, have not shown any evidence of transferrin oversa-
turation when administration rates currently recom-
mended are utilized [19]. Similarly, studies that demon-
strated iron oversaturation with iron sucrose also utilized
flawed methodology [27, 28].
While transferrin oversaturation appears not to occur
with any of the available forms of parenteral iron, it is
clear that nontransferrin bound iron (NTBI) is detect-
able following IV iron administration, even when trans-
ferrin-binding sites are not fully occupied [29]. Although
the precise nature of NTBI is unknown, much of it is
likely represented by protein-bound iron. The presence
of NTBI has been shown in vitro and in vivo for iron
sucrose and iron gluconate, although the ability of the
body to clear iron using non-transferrin mechanisms is
poorly understood, as are the clinical implications, if any,
of NTBI [30–32]. In particular, the relevance of NTBI
to increased oxidative stress, cellular toxicity, and leuko-
cyte function in vivo needs urgent clarification. Studies
should be designed to address these issues in such a way
that head-to-head comparisons of available iron com-
pounds are performed so that clinicians can base product
selection on accurate, comparable data.
WHAT IS THE VALUE OF CONCOMITANT
ASCORBIC ACID THERAPY IN PATIENTS
RECEIVING PARENTERAL IRON?
It has been proposed that some patients with func-
tional iron deficiency (FID) may benefit from adminis-
tration of IV ascorbic acid [33–37]. FID is characterized
by low transferrin levels, but evidence of sufficient or
excess tissue iron usually manifest by ferritin levels above
200 ng/mL. Although the inadequate release of iron in
such circumstances may be multifactorial, it is known
that there is a relationship between the metabolism of
iron and that of ascorbic acid. Tissue concentrations of
ascorbic acid are often low in patients with iron overload,
perhaps reflecting increased catabolism of ascorbic acid
by iron [38]. Ascorbic acid is a potent reducing agent,
and it is this characteristic that explains its apparent
ability to release iron from ferritin and mobilize it from
reticuloendothelial sites of storage [39]. Several recent
studies have suggested that patients with FID may bene-
fit from IV ascorbic acid, although dosage recommenda-
tions vary significantly from 100 mg/week to 1500 mg/
week [33–37]. Because ascorbic acid is metabolized to
oxalate, which is poorly dialyzed, it is currently recom-
mended that the maximum daily dose not exceed 150
mg [40, 41]. That would permit up to 300 mg or so
to be given IV thrice weekly with dialysis treatments.
Clearly, such an approach should be undertaken with
careful monitoring of the patient, since the long-term
need for ascorbic acid, and its safety, remain to be dem-
onstrated.
WHAT ARE THE BEST LABORATORY
PARAMETERS FOR GUIDING
IRON THERAPY?
Bone marrow stainable iron and the response to a
therapeutic trial of iron loading are the gold standards
for defining iron responsive anemia, but are not feasible
clinical tools to guide iron therapy and help clinicians
optimize iron availability and minimize iron toxicity.
The iron saturation (Tsat) and the serum ferritin con-
centration are the most commonly used tests for guiding
the prescription of iron in CKD associated anemia [42].
National Kidney Foundation K/DOQI recommended
values to ensure adequate iron are a Tsat 20% 50%
and a serum ferritin level of 100 to 800 ng/mL. Unfortu-
nately, these tests are influenced by multiple factors
other than total body iron status, most notably inflam-
mation or infection and nutritional status. Both serum
ferritin and Tsat are acute-phase reactants, ferritin hav-
ing a positive and Tsat a negative correlation with acute
or chronic inflammation [42]. Thus, the clinician is often
faced with the challenging scenario of a patient unable
to achieve a target hemoglobin (Hb), but who may or
may not benefit from iron administration based on ferri-
tin and/or Tsat. These limitations have led to a search
for other more reliable indicators of iron status in CKD
patients.
The reticulocyte is the short-lived circulating marrow-
derived erythrocyte precursor. It has been suggested that
the reticulocyte Hb content (CHr) reflects the immediate
availability of bone marrow iron, and as such might be
a good parameter for guiding iron therapy. In fact, Fish-
bane et al [43] found that patients whose prescription
was based on the CHr received less iron compared to
those whose prescription was based on the Tsat and
ferritin levels. He concluded that the CHr was a highly
specific and sensitive test for predicting the need for,
and the likely response to, iron therapy [43]. On the other
hand, Mittman et al [44] reported a lower sensitivity and
utility for the CHr, and subsequent studies continue to
present conflicting results [45, 46].
Transferrin receptors are transmembrane glycopro-
teins expressed on the surface of erythroid cells, which,
during cell proliferation, deliver iron for hemoglobin
synthesis. Serum soluble transferrin receptor (sTfR) is
a truncated form of the transferrin receptor, present
and measurable in the circulation. sTfR concentration
is reciprocally related to the supply of iron and increases
significantly in the presence of iron deficiency. sTfR lev-
els are not affected by inflammatory conditions, infec-
tions, or liver disease, and sTfR has been proposed as a
reliable indicator of body iron status and predictor of the
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erythropoietic response to iron administration [47–49].
Suki et al [50] described their experience using sTfR to
guide iron therapy in 25 patients with ferritin levels800
ng/mL and Tsat 20%. Of these, only five (20%) had
a CHr 29 pg; however, 19 (76%) had an sTfR greater
than 5 mg/L (normal, 1.9 to 5.0 mg/L). Of the 17 patients
who were able to receive IV iron, the Hb rose in 14
(82%), the EPO/Hb index fell in 15 (88%), and both an
Hb rise and EPO/Hb index fall occurred in 11 (73%).
Other investigators, however, have failed to confirm the
efficacy of sTfR as a marker of iron deficiency [51]. These
investigators concluded that the erythropoiesis-induced
rise in sTfR negates its value as an indicator of iron
deficiency.
Thus, the serum ferritin and Tsat still remain the most
clinically useful parameters for initiating and monitoring
iron therapy. In anemic patients with a ferritin 800
ng/mL, a Tsat 20%, and no evidence of an active in-
flammatory process, a low CHr or elevated sTfR may
justify a trial of iron therapy.
WHAT IS THE MAXIMUM AMOUNT OF
INTRAVENOUS IRON GLUCONATE OR IRON
SUCROSE THAT CAN BE SAFELY
ADMINISTERED IN A SINGLE DOSE?
The standard regimen for iron replacement (loading)
in maintenance hemodialysis patients is 100 mg iron su-
crose with each dialysis treatment for 10 treatments, or
125 mg of iron gluconate for 8 treatments, administered
over 5 to 10 minute by IV push or by infusion [52, 53].
Less frequent higher dose regimens are more suitable
for patients on home peritoneal or hemodialysis, or those
CKD patients not yet on dialysis.
The experience with higher dose iron gluconate ther-
apy was reported by Folkert et al [21] in 144 patients. The
following doses were infused over a one-hour period: 571
doses of 250 mg, 1 of 312.5 mg, 14 of 375 mg, and 4 of
500 mg. There were four possible drug-related adverse
events, all in the 250 mg infusion group, one of which
(pruritis) was considered by the investigator to preclude
further administration of iron gluconate. In another
study, nine peritoneal dialysis patients received weekly
doses of 250 mg of iron gluconate, diluted in saline and
given over 90 minutes [54]. No adverse events were re-
ported.
The safety of a 200 mg iron sucrose infusion over five
minutes is reasonably established [55]. Domrongkit-
chaiporn et al [56] noted no significant adverse events
in 21 peritoneal dialysis patients treated with two infu-
sions of 500 mg iron sucrose over 120 minutes. In 28
peritoneal dialysis patients, each of whom received 2
infusions of 500 mg iron sucrose over four to five hours,
Prakash et al [23] noted two spontaneously resolving
reactions and one case of anaphylaxis, an incidence sig-
nificantly lower than noted in a group simultaneously
treated with iron dextran. Chandler et al [22] reported
no reactions in 189 patients given iron sucrose, 300 mg,
over 120 minutes, but an increasing frequency of reac-
tions when 400 and 500 mg were administered at the
same rate. Recently Aaronson and Cornell [57] noted
no adverse events in a group of 20 predialysis patients,
each of whom received two infusions of iron sucrose, 500
mg, over four hours. This experience was subsequently
extended and reproduced in a total of 155 infusions in
76 predialysis (N  58) and peritoneal dialysis (N  18)
patients (Charytan C, personal communication, May 7,
2003). It is possible that the safety of the 200 mg rapid
5-minute infusions, in contrast to the requirement for
slower infusions with doses in excess of 300 mg, may
reflect the as yet incompletely understood kinetics of iron
release and transfer from the drug complex to transferrin
and to tissue stores. Thus, doses below 200 mg are not
rate limited, whereas rate-limiting factors come into play
at doses in excess of 300 mg.
From the available data it appears that 200 mg iron
sucrose can be safely administered by a rapid 5-minute
push, and similar data support the safety of 125 mg iron
gluconate infusion over 10 minutes and 250 mg over 60
minutes, respectively. The experience with higher doses
of either drug is somewhat limited. It appears, however,
that iron sucrose doses between 200 and 400 mg may be
infused safely over two hours, whereas doses of 400 to
500 mg are best infused over 240 minutes. For iron gluco-
nate, infusions of 312.5 to 500 mg have been safely in-
fused over one hour in a small number of patients, but
slower infusion rates may be preferable until additional
studies on the safety of this approach are available.
ARE THERE CLINICALLY IMPORTANT
DIFFERENCES BETWEEN IRON GLUCONATE
(FERRLECIT) AND IRON SUCROSE
(VENOFER)?
Although not fully defined, iron gluconate and iron
sucrose appear to have some differing biochemical char-
acteristics and pharmacokinetics. These include differ-
ences in molecular structure and weight, kinetics of iron
release from the drug complex, binding to transferrin,
and clearance from plasma to tissues [3, 4]. Both iron
preparations have been demonstrated to transfer iron
directly to transferrin, result in detectable quantities of
NTBI in the circulation, produce reactive oxygen species,
and contribute to oxidant stress, in vitro lipid peroxida-
tion, and cell death [30, 31]. Some of these effects occur at
extremely high concentrations and/or are very transient,
thus unlikely to have a clinical effect. The reported lipid
peroxidation and cell cytotoxic effects occurred at in
vitro concentrations orders of magnitude above those
associated with any of the currently utilized therapeutic
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regimens [58]. To date, there are no published demon-
strable correlations between any of the above biochemi-
cal or in vitro phenomena and clinical outcomes in terms
of safety or efficacy.
On the basis of the reported North American clinical
trials and a 50-year European experience, it is clear that
both drugs are efficacious in replenishing body iron
stores, correcting anemia, improving the response to
erythropoietin therapy, and have a clearly superior safety
profile compared to the dextrans, with a significantly
lower incidence of overall, severe, or life-threatening
drug-related adverse events [52, 53]. There is currently
no definitive data to suggest that one agent is safer or
more efficacious than the other, but there are virtually no
head-to-head comparative clinical studies of iron sucrose
versus iron gluconate. Kosch et al [59] reported their
observations on 55 patients treated with iron gluconate
or iron sucrose with somewhat dissimilar regimens. They
noted no differences in safety or efficacy, although the
patients receiving iron sucrose achieved study end points
for Hb, Tsat, or ferritin faster and at lower total doses of
iron compared with the group treated with the gluconate
preparation. There were no drug-related adverse events
in either group.
The available North American experience suggests
that patients with previous reactions to iron dextrans
will generally tolerate the newer iron agents; however,
they appear to be somewhat more likely to have mild
reactions or develop intolerance after administration of
iron gluconate than patients without a history of dextran
intolerance [60]. About 0.8% percent of patients receiv-
ing iron gluconate develop drug-related reactions pre-
cluding its further administration, whereas this is rare
following iron sucrose administration (Aronoff G, oral
presentation, March 2003). Patients with drug-related
reactions precluding the further use of iron gluconate,
or both gluconate and dextran, may be able to tolerate
iron sucrose [61]. We are not aware of any reported
North American experience regarding the use of iron
gluconate in patients with significant reactions to iron
sucrose. It must again be pointed out, however, that
the reported experiences are based on similar but not
identical patient populations.
IN PATIENTS WITH A TSAT 20% AND A
FERRITIN 500 NG/ML, IS GIVING
IRON FUTILE?
The National Kidney Foundation K/DOQI guidelines
recommend not administering iron if the ferritin is800
ng/mL [42]. Fishbane [62] has suggested that there is no
published systematic evidence demonstrating a hemato-
logic benefit, defined as a rise in hemoglobin or decrease
in erythropoietin requirements, with iron administration
when ferritin level exceeds 500 ng/mL. On the other
hand, there is data that raising the Tsat beyond 20%, to
30% to 50% is associated with a progressive improve-
ment in hemoglobin levels and/or a decrease in erythro-
poietin dose even as ferritin levels exceed 500 to 800
ng/mL [63]. These conflicting observations have led to
unclear and ambiguous recommendations for clinicians.
There are at least two possible and competing inter-
pretations of these disparate findings. The first is that
such situations represent a state of functional iron defi-
ciency (i.e., a blockade to the release and utilization of
iron stored in the reticuloendothelial system). This view
is supported by the limited reports of such patients re-
sponding to continued iron therapy, and the observation
that ascorbic acid infusions facilitate iron mobilization
and its incorporation into hemoglobin in this setting
[33–35]. The more commonly accepted interpretation is
that a low Tsat and high ferritin represent an acute-
phase response to inflammation, a situation in which
further iron administration is futile. Unfortunately, the
only definitive way to distinguish between these two pos-
sibilities is by a therapeutic trial of iron therapy. This
approach is problematic, however, given the concerns
that excess iron may be pro-inflammatory and facilitate
bacterial infections (see below). Attempts to distinguish
a true state of functional iron deficiency from a low Tsat
and suppressed hematopoietic response due to inflam-
mation by the use of the CHr or sTfR have yielded
conflicting results as well (see above).
Currently, the most reasonable approach to the patient
presenting with a ferritin greater than 800 ng/mL and a
low Tsat is to initiate a thorough investigation for an
inflammatory process. The latter may be occult or appear
misleadingly minor and insignificant, such as small, scabbed
lesions on the feet or over a vascular access. Vascular
access infections in particular may not be apparent, as
with internally infected catheters or arteriovenous grafts
(AVGs). In one study of patients with erythropoietin
resistance, no clinical signs or symptoms of localized
or systemic infection, and asymptomatic nonfunctioning
AVGs, fully 75% had positive indium-labeled white blood
cell scans of the AVG with bacteriologically proven in-
fection following surgical AVG resection [64]. Following
resection of the AVGs the mean hemoglobin and serum
albumin values rose, while the erythropoietin dose, se-
rum ferritin, and C-reactive protein (CRP) levels de-
clined. Thus, laboratory markers, such as the serum albu-
min and CRP levels, indium scanning, and/or removal of
non-functional AVGs and catheters should be included
in the evaluation and management of anemic erythropoi-
etin resistant patients with a low Tsat and high ferritin.
In the occasional patient with no evidence of an active
inflammatory process following a thorough clinical, labo-
ratory, and imaging evaluation, measurement of CHr
and/or sTfR may be useful and guide the decision to
attempt a therapeutic trial of intravenous iron.
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DO THE CURRENTLY RECOMMENDED
REGIMENS FOR PARENTERAL IRON
THERAPY LEAD TO A STATE OF IRON
EXCESS AND/OR LONG-TERM TOXICITY?
Hemosiderosis, a state of total body iron excess with
predominant iron deposition in the reticuloendothelial
system and without evidence of organ dysfunction, and
hemochromatosis, a state of excessive parenchymal cell
iron deposition causing tissue damage and organ dys-
function, are the best-known consequences of total body
iron overload. Hemosiderosis was not uncommonly re-
ported in ESRD patients in the pre-erythropoietin era,
usually as a consequence of frequent red blood cell trans-
fusions, rarely following IV iron therapy [65–68]. By
contrast, there have been no such reports since the intro-
duction of erythropoietin for routine clinical use, and it
has been shown that erythropoietin administration mobi-
lizes and reduces tissue iron stores [1, 69].
The apparent discrepancy in the incidence of these
complications during the pre- and post-erythropoietin
periods may have two likely explanations. First, the pre-
erythropoietin transfusion requirements of maintenance
hemodialysis patients of 1 to 2 or more units per month
was equivalent to the administration of 3 to more than
6 g parenteral iron per year. Second, in the absence
of erythropoietin-stimulated erythropoiesis, tissue iron,
whether originating from the breakdown of transfused
red cells or parenteral iron therapy, could not be mobi-
lized. It should be noted that the reported serum ferritin
levels in these patients were in the range of 2000 to more
than 5000 ng/mL. By contrast, currently recommended
regimens for parenteral iron therapy result in the admin-
istration of less than 3 g per year and include the sugges-
tion that ferritin levels do not exceed 800 ng/mL.
Recently, the focus of debate regarding potential iron
toxicity revolves around a concern that it may increase
susceptibility to infectious complications and cardio-
vascular morbidity and mortality. Enhanced bacterial
growth and leukocyte dysfunction with inhibition of
phagocytosis are demonstrable in vitro characteristics of
iron preparations [70, 71]. In vitro, all iron preparations
have the capacity to cause the production of reactive
oxygen species, increase oxidative stress, consume anti-
oxidants, and at very high doses, promote lipid peroxida-
tion and cell death. These observations have led to a
concern that these in vitro phenomenona might be clues
to possible clinical effects leading to an increased suscep-
tibility to infectious complications, accelerated athero-
sclerosis, and cardiovascular morbidity. Feldman et al
[72] reported increased rates of hospitalization and mor-
tality in patients billed for more than 1 g of IV iron over
a 6-month interval in retrospective reviews of two large
cohorts. Similarly, an increase in infectious complications
was reported by Canziani et al [73] in patients receiving
more than 1 g of IV iron over a 6-month period.
Unfortunately, despite attempts at adjusting for co-
morbidities, this type of retrospective administrative da-
tabase analysis cannot distinguish between cause and
effect. Did the higher iron doses contribute to the in-
creased complication rates, or were sicker patients with
suppressed erythropoiesis the ones requiring more ag-
gressive therapy, and destined to a poorer outcome inde-
pendent of iron administration? Support for the latter
possibility, or at least for a more complex relationship
between iron treatment and survival, is the observation
by Sun et al [74] in a cohort of the 14,886 hemodialysis
patients in the DCI database between 1997 and 2000.
Cardiovascular and infectious death rates were increased
in the patients receiving no iron and in those receiving
greater than 5 g per year. There was no difference in
mortality from these causes among those receiving from
150 mg to 5 g of iron per year. Recently, Feldman et al
[75] indicated that the apparent relationship between
increased hospitalization rates and mortality and pre-
sumed higher administered doses of IV iron was not
supported by more extensive statistical analysis. Theo-
retical support for the absence of a noxious clinical effect
of iron is suggested by studies reported by Drueke et al
[76], who demonstrate a lack of correlation between the
production of reactive oxygen species and iron doses
below 5 g per year.
There are additional studies that demonstrate a lack
of correlation between iron administration and body iron
stores and infectious complications. Hoen et al [77], in
a multicenter prospective study of 985 patients on hemo-
dialysis, found that infectious complications correlated
with central venous catheters, a history of previous bac-
teremia, AVGs, and immunosuppression, but not with
ferritin levels or IV iron administration. Similarly, Vy-
chytil and Haag-Weber [78] found no correlation be-
tween iron administration and the incidence of infectious
complications in patients on maintenance peritoneal di-
alysis. Aronoff et al reported the rate of infection-related
hospital admissions and mortality, in a group of 665
patients who received 8583 100 mg doses of iron sucrose
during a 239 patient-year experience, to be approximately
one-half and two-thirds, respectively, of that reported by
the United States Renal Data System (USRDS) in a large
multi-year cohort of hemodialysis patients (Aronoff G,
oral presentation, March 2003).
CONCLUSION
Thus, there is no definitive data demonstrating clini-
cally negative consequences of the currently recom-
mended regimens for iron administration. Nevertheless,
logic and intuition suggest that at some level a state of
total body iron excess and consequent toxicity must exist.
The pre-erythropoietin experience suggests that this re-
quires annual iron doses well in excess of 5 g, and serum
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ferritin levels greater than 2000 to 5000 ng/mL. Prudence
dictates that aggressive iron therapy be withheld in the
presence of an active inflammatory state and that pa-
tients be carefully monitored if currently recommended
ferritin and Tsat ceilings are exceeded.
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